APTEΞUS is a Biotech specialized in drug discovery and repositionin in the field of rare monogenic diseases for which it is possible to measure the cause of the disease on cells of patients in culture. APTEEUS is currently particularly committed to hereditary metabolic diseases and genodermatoses. One of the objectives of APTEEUS is to identify new avenues of treatment for these diseases and less rare diseases. APTEEUS offers access to automated cell screening technology in partnership with patient organizations, research teams and pharmaceutical companies. Through use of primary cells directly from patients, APTEEUS is able to reproduce in vitro the physiopathology of a patient’s disease and to measure the effect of specific molecules.
The toolbox has been developed through funding from the EJP RD project.
The European Joint Programme on Rare Diseases is an initiative that has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement N°825575
IMT Cookie Overview
Please also read this disclaimer carefully before using the EJPRD IMT